期刊
FUTURE MICROBIOLOGY
卷 6, 期 6, 页码 635-651出版社
FUTURE MEDICINE LTD
DOI: 10.2217/FMB.11.27
关键词
antibiotic development; antibiotic resistance; anti-infective; antimicrobial peptide; lantibiotic; nanoparticle; narrow spectrum; peptide formulation; peptide stability; peptidomimetics; specifically targeted antimicrobial peptide; toxicity
类别
资金
- US NIH SBIR [1R43DE019970, 1R43DE020982]
Since the discovery of magainins, cecropins and defensins 30 years ago, antimicrobial peptides (AMPs) have been hailed as a potential solution to the dearth of novel antibiotic development. AMPs have shown robust activity against a wide variety of pathogens, including drug-resistant bacteria. Unlike small-molecule antibiotics, however, AMPs have failed to translate this success to the clinic. Only the polymyxins, gramicidins, nisin and daptomycin are currently approved for medical use; the latter is the only example to have been developed in the last several decades. Nonetheless, researchers continue to isolate, modify and develop novel AMPs for therapeutic applications. Efforts have focused on increasing stability, reducing cytotoxicity, improving antimicrobial activity and incorporating AMPs in novel formulations, including nanoscale particles. As peptide synthesis and recombinant production methodologies improve, and more relevant bioassays become available, it becomes increasingly likely that AMPs will break the regulatory barrier and enter the marketplace as valuable antimicrobial weapons in the next 10 years.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据